{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:19:09Z","timestamp":1760645949829},"reference-count":11,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":10768,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1983,2]]},"abstract":"<jats:p>Not only has insomnia become much more frequent in the last hundred years but its causes have also changed considerably. In the treatment of insomnia, benzodiazepines\u2010because of their additional anxiolytic effect\u2010offer substantial advantages over other sleep\u2010inducing agents. The residual fraction\u2010the quotient of plasma concentration at 12 h after drug intake to maximum plasma concentration\u2010makes it possible to differentiate between the benzodiazepines according to their suitability as anxiolytics or hypnotics. Midazolam has the lowest residual fraction of all known benzodiazepines and thus, administered in the appropriate dosage, also has the shortest duration of activity.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1983.tb02265.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T19:40:26Z","timestamp":1343331626000},"source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetic and clinical considerations in the choice of a hypnotic."],"prefix":"10.1111","volume":"16","author":[{"given":"R","family":"Amrein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Leishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"85","article-title":"Pharmacokinetics and pharmacodynamics of flurazepam in man, II. Investigations of the relative efficacy of flurazepam, desalkylflurazepam and placebo under steady\u2010state conditions.","volume":"9","author":"AMREIN R.","year":"1983","journal-title":"Drugs clin. exp. Res."},{"key":"e_1_2_1_3_1","first-page":"1163","article-title":"Zur Pharmacokinetik von Schlafmitteln.","volume":"56","author":"AMREIN R.","year":"1980","journal-title":"Z. Allgemeinmed."},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-011-7238-7_6"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01060092"},{"key":"e_1_2_1_6_1","first-page":"2383","article-title":"Bioavailability of various galenic formulations of flunitrazepam.","volume":"27","author":"CANO J.P.","year":"1977","journal-title":"Arzneimittel-Forsch."},{"key":"e_1_2_1_7_1","volume-title":"Benzodiazepines\u2010From Molecular Biology to Clinical Practice","author":"DETTLI L."},{"key":"e_1_2_1_8_1","volume-title":"Gallup Study of Sleeping Habits","author":"GALLUP ORGANIZATION","year":"1979"},{"key":"e_1_2_1_9_1","first-page":"211","volume-title":"Biological Effects of Drugs in Relation to their Plasma Concentrations","author":"GARATTINI S.","year":"1973"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb02270.x"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977214430"},{"key":"e_1_2_1_12_1","first-page":"687","article-title":"Absorption and excretion of 7\u2010chloro\u20101, 3\u2010dihydro\u20103\u2010hydroxy\u20105\u2010phenyl\u2010 2H\u20101, 4\u2010benzodiazepin\u20102\u2010one (oxazepam) in humans.","volume":"22","author":"KNOWLES J.A.","year":"1972","journal-title":"Arzneimittel-Forsch."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1983.tb02265.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1983.tb02265.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T07:51:54Z","timestamp":1697788314000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1983.tb02265.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,2]]},"references-count":11,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[1983,2]]}},"alternative-id":["10.1111\/j.1365-2125.1983.tb02265.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb02265.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,2]]}}}